Global Minichromosomal Technology Market
Global Minichromosomal Technology Market

Minichromosomal Technology Comprehensive Study by Type (Reagents & Consumables, Software & Systems, Services), Application (Cell Line Engineering, Genetic Engineering, Diagnostic Applications, Drug Discovery & Development, Others), End Use (Pharmaceutical Companies, Biotechnology Companies, Academic & Government Research Institutes) Players and Region - Global Market Outlook to 2026

Minichromosomal Technology Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jul 2021 Edition 207 Pages 217 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Minichromosomal Technology Market Scope
Genetic engineering is a scientific tool that is utilised in a wide range of fields, including plant, animal, and human sciences. Plant genetic engineering has revolutionised plant science, with the first generation of transgenic crops being the most widely accepted technique in contemporary agriculture. However, genetic engineering has certain limits, and new methods are still needed to address difficulties such as gene stacking, transgene location effects, and insertion-site complexity. Because of the plasticity of the genome in plants compared to other taxa and the ability to manipulate and analyse such chromosomes throughout the life cycle and at various stages of development, engineered minichromosomes, also known as artificial chromosomes or synthetic chromosomes, are likely to have numerous applications in both basic and applied research. A minichromosome is a very tiny form of a chromosome either through de novo synthesis utilising cloned chromosome components or by telomere-mediated truncation of endogenous chromosomes.

The Minichromosomal Technology market study is segmented by Type (Reagents & Consumables, Software & Systems and Services), by Application (Cell Line Engineering, Genetic Engineering, Diagnostic Applications, Drug Discovery & Development and Others) and major geographies with country level break-up.

The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Minichromosomal Technology market throughout the predicted period.

Thermo Fisher Scientific (United States), Merck KGaA (Germany), Horizon Discovery Limited (United Kingdom), Lonza (Switzerland), GenScript (United States), Eurofins Scientific (Luxembourg), Sangamo Therapeutics (United States), Editas Medicine (United States), CRISPR Therapeutics (Switzerland) and Precision Biosciences (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Oxford Genetics (United Kingdom), Agilent Technologies (United States), Danaher (United States), ToolGen (South Korea) and Genecopoeia (United States).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AMA Research has segmented the market of Global Minichromosomal Technology market by Type, Application and Region.

On the basis of geography, the market of Minichromosomal Technology has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).




Market Trend
  • Increasing Applications in Biopharmaceutical Segment

Market Drivers
  • Rising Government Expenditure Genomics Projects
  • Growth in Biotechnology Industry

Opportunities
  • Increasing Biotech Infrastructure Cross Asian Regions

Restraints
  • Lack of Trained Professionals
  • High Initial Investment

Challenges
  • Fierce Competitive Pressure


Key Target Audience
Biotechnology Companies, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

Frequently Asked Questions (FAQ):

1. Is it possible to have certain customization in the study?
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.

2. How big is the Minichromosomal Technology Market?
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.

Report Objectives / Segmentation Covered
By Type
  • Reagents & Consumables
  • Software & Systems
  • Services
By Application
  • Cell Line Engineering
  • Genetic Engineering
  • Diagnostic Applications
  • Drug Discovery & Development
  • Others
By End Use
  • Pharmaceutical Companies
  • Biotechnology Companies
  • Academic & Government Research Institutes

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Government Expenditure Genomics Projects
      • 3.2.2. Growth in Biotechnology Industry
    • 3.3. Market Challenges
      • 3.3.1. Fierce Competitive Pressure
    • 3.4. Market Trends
      • 3.4.1. Increasing Applications in Biopharmaceutical Segment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Minichromosomal Technology, by Type, Application, End Use and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Minichromosomal Technology (Value)
      • 5.2.1. Global Minichromosomal Technology by: Type (Value)
        • 5.2.1.1. Reagents & Consumables
        • 5.2.1.2. Software & Systems
        • 5.2.1.3. Services
      • 5.2.2. Global Minichromosomal Technology by: Application (Value)
        • 5.2.2.1. Cell Line Engineering
        • 5.2.2.2. Genetic Engineering
        • 5.2.2.3. Diagnostic Applications
        • 5.2.2.4. Drug Discovery & Development
        • 5.2.2.5. Others
      • 5.2.3. Global Minichromosomal Technology by: End Use (Value)
        • 5.2.3.1. Pharmaceutical Companies
        • 5.2.3.2. Biotechnology Companies
        • 5.2.3.3. Academic & Government Research Institutes
      • 5.2.4. Global Minichromosomal Technology Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Minichromosomal Technology: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Thermo Fisher Scientific (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merck KGaA (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Horizon Discovery Limited (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Lonza (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GenScript (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Eurofins Scientific (Luxembourg)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sangamo Therapeutics (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Editas Medicine (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. CRISPR Therapeutics (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Precision Biosciences (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Minichromosomal Technology Sale, by Type, Application, End Use and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Minichromosomal Technology (Value)
      • 7.2.1. Global Minichromosomal Technology by: Type (Value)
        • 7.2.1.1. Reagents & Consumables
        • 7.2.1.2. Software & Systems
        • 7.2.1.3. Services
      • 7.2.2. Global Minichromosomal Technology by: Application (Value)
        • 7.2.2.1. Cell Line Engineering
        • 7.2.2.2. Genetic Engineering
        • 7.2.2.3. Diagnostic Applications
        • 7.2.2.4. Drug Discovery & Development
        • 7.2.2.5. Others
      • 7.2.3. Global Minichromosomal Technology by: End Use (Value)
        • 7.2.3.1. Pharmaceutical Companies
        • 7.2.3.2. Biotechnology Companies
        • 7.2.3.3. Academic & Government Research Institutes
      • 7.2.4. Global Minichromosomal Technology Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Minichromosomal Technology: by Type(USD Million)
  • Table 2. Minichromosomal Technology Reagents & Consumables , by Region USD Million (2015-2020)
  • Table 3. Minichromosomal Technology Software & Systems , by Region USD Million (2015-2020)
  • Table 4. Minichromosomal Technology Services , by Region USD Million (2015-2020)
  • Table 5. Minichromosomal Technology: by Application(USD Million)
  • Table 6. Minichromosomal Technology Cell Line Engineering , by Region USD Million (2015-2020)
  • Table 7. Minichromosomal Technology Genetic Engineering , by Region USD Million (2015-2020)
  • Table 8. Minichromosomal Technology Diagnostic Applications , by Region USD Million (2015-2020)
  • Table 9. Minichromosomal Technology Drug Discovery & Development , by Region USD Million (2015-2020)
  • Table 10. Minichromosomal Technology Others , by Region USD Million (2015-2020)
  • Table 11. Minichromosomal Technology: by End Use(USD Million)
  • Table 12. Minichromosomal Technology Pharmaceutical Companies , by Region USD Million (2015-2020)
  • Table 13. Minichromosomal Technology Biotechnology Companies , by Region USD Million (2015-2020)
  • Table 14. Minichromosomal Technology Academic & Government Research Institutes , by Region USD Million (2015-2020)
  • Table 15. South America Minichromosomal Technology, by Country USD Million (2015-2020)
  • Table 16. South America Minichromosomal Technology, by Type USD Million (2015-2020)
  • Table 17. South America Minichromosomal Technology, by Application USD Million (2015-2020)
  • Table 18. South America Minichromosomal Technology, by End Use USD Million (2015-2020)
  • Table 19. Brazil Minichromosomal Technology, by Type USD Million (2015-2020)
  • Table 20. Brazil Minichromosomal Technology, by Application USD Million (2015-2020)
  • Table 21. Brazil Minichromosomal Technology, by End Use USD Million (2015-2020)
  • Table 22. Argentina Minichromosomal Technology, by Type USD Million (2015-2020)
  • Table 23. Argentina Minichromosomal Technology, by Application USD Million (2015-2020)
  • Table 24. Argentina Minichromosomal Technology, by End Use USD Million (2015-2020)
  • Table 25. Rest of South America Minichromosomal Technology, by Type USD Million (2015-2020)
  • Table 26. Rest of South America Minichromosomal Technology, by Application USD Million (2015-2020)
  • Table 27. Rest of South America Minichromosomal Technology, by End Use USD Million (2015-2020)
  • Table 28. Asia Pacific Minichromosomal Technology, by Country USD Million (2015-2020)
  • Table 29. Asia Pacific Minichromosomal Technology, by Type USD Million (2015-2020)
  • Table 30. Asia Pacific Minichromosomal Technology, by Application USD Million (2015-2020)
  • Table 31. Asia Pacific Minichromosomal Technology, by End Use USD Million (2015-2020)
  • Table 32. China Minichromosomal Technology, by Type USD Million (2015-2020)
  • Table 33. China Minichromosomal Technology, by Application USD Million (2015-2020)
  • Table 34. China Minichromosomal Technology, by End Use USD Million (2015-2020)
  • Table 35. Japan Minichromosomal Technology, by Type USD Million (2015-2020)
  • Table 36. Japan Minichromosomal Technology, by Application USD Million (2015-2020)
  • Table 37. Japan Minichromosomal Technology, by End Use USD Million (2015-2020)
  • Table 38. India Minichromosomal Technology, by Type USD Million (2015-2020)
  • Table 39. India Minichromosomal Technology, by Application USD Million (2015-2020)
  • Table 40. India Minichromosomal Technology, by End Use USD Million (2015-2020)
  • Table 41. South Korea Minichromosomal Technology, by Type USD Million (2015-2020)
  • Table 42. South Korea Minichromosomal Technology, by Application USD Million (2015-2020)
  • Table 43. South Korea Minichromosomal Technology, by End Use USD Million (2015-2020)
  • Table 44. Taiwan Minichromosomal Technology, by Type USD Million (2015-2020)
  • Table 45. Taiwan Minichromosomal Technology, by Application USD Million (2015-2020)
  • Table 46. Taiwan Minichromosomal Technology, by End Use USD Million (2015-2020)
  • Table 47. Australia Minichromosomal Technology, by Type USD Million (2015-2020)
  • Table 48. Australia Minichromosomal Technology, by Application USD Million (2015-2020)
  • Table 49. Australia Minichromosomal Technology, by End Use USD Million (2015-2020)
  • Table 50. Rest of Asia-Pacific Minichromosomal Technology, by Type USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific Minichromosomal Technology, by Application USD Million (2015-2020)
  • Table 52. Rest of Asia-Pacific Minichromosomal Technology, by End Use USD Million (2015-2020)
  • Table 53. Europe Minichromosomal Technology, by Country USD Million (2015-2020)
  • Table 54. Europe Minichromosomal Technology, by Type USD Million (2015-2020)
  • Table 55. Europe Minichromosomal Technology, by Application USD Million (2015-2020)
  • Table 56. Europe Minichromosomal Technology, by End Use USD Million (2015-2020)
  • Table 57. Germany Minichromosomal Technology, by Type USD Million (2015-2020)
  • Table 58. Germany Minichromosomal Technology, by Application USD Million (2015-2020)
  • Table 59. Germany Minichromosomal Technology, by End Use USD Million (2015-2020)
  • Table 60. France Minichromosomal Technology, by Type USD Million (2015-2020)
  • Table 61. France Minichromosomal Technology, by Application USD Million (2015-2020)
  • Table 62. France Minichromosomal Technology, by End Use USD Million (2015-2020)
  • Table 63. Italy Minichromosomal Technology, by Type USD Million (2015-2020)
  • Table 64. Italy Minichromosomal Technology, by Application USD Million (2015-2020)
  • Table 65. Italy Minichromosomal Technology, by End Use USD Million (2015-2020)
  • Table 66. United Kingdom Minichromosomal Technology, by Type USD Million (2015-2020)
  • Table 67. United Kingdom Minichromosomal Technology, by Application USD Million (2015-2020)
  • Table 68. United Kingdom Minichromosomal Technology, by End Use USD Million (2015-2020)
  • Table 69. Netherlands Minichromosomal Technology, by Type USD Million (2015-2020)
  • Table 70. Netherlands Minichromosomal Technology, by Application USD Million (2015-2020)
  • Table 71. Netherlands Minichromosomal Technology, by End Use USD Million (2015-2020)
  • Table 72. Rest of Europe Minichromosomal Technology, by Type USD Million (2015-2020)
  • Table 73. Rest of Europe Minichromosomal Technology, by Application USD Million (2015-2020)
  • Table 74. Rest of Europe Minichromosomal Technology, by End Use USD Million (2015-2020)
  • Table 75. MEA Minichromosomal Technology, by Country USD Million (2015-2020)
  • Table 76. MEA Minichromosomal Technology, by Type USD Million (2015-2020)
  • Table 77. MEA Minichromosomal Technology, by Application USD Million (2015-2020)
  • Table 78. MEA Minichromosomal Technology, by End Use USD Million (2015-2020)
  • Table 79. Middle East Minichromosomal Technology, by Type USD Million (2015-2020)
  • Table 80. Middle East Minichromosomal Technology, by Application USD Million (2015-2020)
  • Table 81. Middle East Minichromosomal Technology, by End Use USD Million (2015-2020)
  • Table 82. Africa Minichromosomal Technology, by Type USD Million (2015-2020)
  • Table 83. Africa Minichromosomal Technology, by Application USD Million (2015-2020)
  • Table 84. Africa Minichromosomal Technology, by End Use USD Million (2015-2020)
  • Table 85. North America Minichromosomal Technology, by Country USD Million (2015-2020)
  • Table 86. North America Minichromosomal Technology, by Type USD Million (2015-2020)
  • Table 87. North America Minichromosomal Technology, by Application USD Million (2015-2020)
  • Table 88. North America Minichromosomal Technology, by End Use USD Million (2015-2020)
  • Table 89. United States Minichromosomal Technology, by Type USD Million (2015-2020)
  • Table 90. United States Minichromosomal Technology, by Application USD Million (2015-2020)
  • Table 91. United States Minichromosomal Technology, by End Use USD Million (2015-2020)
  • Table 92. Canada Minichromosomal Technology, by Type USD Million (2015-2020)
  • Table 93. Canada Minichromosomal Technology, by Application USD Million (2015-2020)
  • Table 94. Canada Minichromosomal Technology, by End Use USD Million (2015-2020)
  • Table 95. Mexico Minichromosomal Technology, by Type USD Million (2015-2020)
  • Table 96. Mexico Minichromosomal Technology, by Application USD Million (2015-2020)
  • Table 97. Mexico Minichromosomal Technology, by End Use USD Million (2015-2020)
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Minichromosomal Technology: by Type(USD Million)
  • Table 109. Minichromosomal Technology Reagents & Consumables , by Region USD Million (2021-2026)
  • Table 110. Minichromosomal Technology Software & Systems , by Region USD Million (2021-2026)
  • Table 111. Minichromosomal Technology Services , by Region USD Million (2021-2026)
  • Table 112. Minichromosomal Technology: by Application(USD Million)
  • Table 113. Minichromosomal Technology Cell Line Engineering , by Region USD Million (2021-2026)
  • Table 114. Minichromosomal Technology Genetic Engineering , by Region USD Million (2021-2026)
  • Table 115. Minichromosomal Technology Diagnostic Applications , by Region USD Million (2021-2026)
  • Table 116. Minichromosomal Technology Drug Discovery & Development , by Region USD Million (2021-2026)
  • Table 117. Minichromosomal Technology Others , by Region USD Million (2021-2026)
  • Table 118. Minichromosomal Technology: by End Use(USD Million)
  • Table 119. Minichromosomal Technology Pharmaceutical Companies , by Region USD Million (2021-2026)
  • Table 120. Minichromosomal Technology Biotechnology Companies , by Region USD Million (2021-2026)
  • Table 121. Minichromosomal Technology Academic & Government Research Institutes , by Region USD Million (2021-2026)
  • Table 122. South America Minichromosomal Technology, by Country USD Million (2021-2026)
  • Table 123. South America Minichromosomal Technology, by Type USD Million (2021-2026)
  • Table 124. South America Minichromosomal Technology, by Application USD Million (2021-2026)
  • Table 125. South America Minichromosomal Technology, by End Use USD Million (2021-2026)
  • Table 126. Brazil Minichromosomal Technology, by Type USD Million (2021-2026)
  • Table 127. Brazil Minichromosomal Technology, by Application USD Million (2021-2026)
  • Table 128. Brazil Minichromosomal Technology, by End Use USD Million (2021-2026)
  • Table 129. Argentina Minichromosomal Technology, by Type USD Million (2021-2026)
  • Table 130. Argentina Minichromosomal Technology, by Application USD Million (2021-2026)
  • Table 131. Argentina Minichromosomal Technology, by End Use USD Million (2021-2026)
  • Table 132. Rest of South America Minichromosomal Technology, by Type USD Million (2021-2026)
  • Table 133. Rest of South America Minichromosomal Technology, by Application USD Million (2021-2026)
  • Table 134. Rest of South America Minichromosomal Technology, by End Use USD Million (2021-2026)
  • Table 135. Asia Pacific Minichromosomal Technology, by Country USD Million (2021-2026)
  • Table 136. Asia Pacific Minichromosomal Technology, by Type USD Million (2021-2026)
  • Table 137. Asia Pacific Minichromosomal Technology, by Application USD Million (2021-2026)
  • Table 138. Asia Pacific Minichromosomal Technology, by End Use USD Million (2021-2026)
  • Table 139. China Minichromosomal Technology, by Type USD Million (2021-2026)
  • Table 140. China Minichromosomal Technology, by Application USD Million (2021-2026)
  • Table 141. China Minichromosomal Technology, by End Use USD Million (2021-2026)
  • Table 142. Japan Minichromosomal Technology, by Type USD Million (2021-2026)
  • Table 143. Japan Minichromosomal Technology, by Application USD Million (2021-2026)
  • Table 144. Japan Minichromosomal Technology, by End Use USD Million (2021-2026)
  • Table 145. India Minichromosomal Technology, by Type USD Million (2021-2026)
  • Table 146. India Minichromosomal Technology, by Application USD Million (2021-2026)
  • Table 147. India Minichromosomal Technology, by End Use USD Million (2021-2026)
  • Table 148. South Korea Minichromosomal Technology, by Type USD Million (2021-2026)
  • Table 149. South Korea Minichromosomal Technology, by Application USD Million (2021-2026)
  • Table 150. South Korea Minichromosomal Technology, by End Use USD Million (2021-2026)
  • Table 151. Taiwan Minichromosomal Technology, by Type USD Million (2021-2026)
  • Table 152. Taiwan Minichromosomal Technology, by Application USD Million (2021-2026)
  • Table 153. Taiwan Minichromosomal Technology, by End Use USD Million (2021-2026)
  • Table 154. Australia Minichromosomal Technology, by Type USD Million (2021-2026)
  • Table 155. Australia Minichromosomal Technology, by Application USD Million (2021-2026)
  • Table 156. Australia Minichromosomal Technology, by End Use USD Million (2021-2026)
  • Table 157. Rest of Asia-Pacific Minichromosomal Technology, by Type USD Million (2021-2026)
  • Table 158. Rest of Asia-Pacific Minichromosomal Technology, by Application USD Million (2021-2026)
  • Table 159. Rest of Asia-Pacific Minichromosomal Technology, by End Use USD Million (2021-2026)
  • Table 160. Europe Minichromosomal Technology, by Country USD Million (2021-2026)
  • Table 161. Europe Minichromosomal Technology, by Type USD Million (2021-2026)
  • Table 162. Europe Minichromosomal Technology, by Application USD Million (2021-2026)
  • Table 163. Europe Minichromosomal Technology, by End Use USD Million (2021-2026)
  • Table 164. Germany Minichromosomal Technology, by Type USD Million (2021-2026)
  • Table 165. Germany Minichromosomal Technology, by Application USD Million (2021-2026)
  • Table 166. Germany Minichromosomal Technology, by End Use USD Million (2021-2026)
  • Table 167. France Minichromosomal Technology, by Type USD Million (2021-2026)
  • Table 168. France Minichromosomal Technology, by Application USD Million (2021-2026)
  • Table 169. France Minichromosomal Technology, by End Use USD Million (2021-2026)
  • Table 170. Italy Minichromosomal Technology, by Type USD Million (2021-2026)
  • Table 171. Italy Minichromosomal Technology, by Application USD Million (2021-2026)
  • Table 172. Italy Minichromosomal Technology, by End Use USD Million (2021-2026)
  • Table 173. United Kingdom Minichromosomal Technology, by Type USD Million (2021-2026)
  • Table 174. United Kingdom Minichromosomal Technology, by Application USD Million (2021-2026)
  • Table 175. United Kingdom Minichromosomal Technology, by End Use USD Million (2021-2026)
  • Table 176. Netherlands Minichromosomal Technology, by Type USD Million (2021-2026)
  • Table 177. Netherlands Minichromosomal Technology, by Application USD Million (2021-2026)
  • Table 178. Netherlands Minichromosomal Technology, by End Use USD Million (2021-2026)
  • Table 179. Rest of Europe Minichromosomal Technology, by Type USD Million (2021-2026)
  • Table 180. Rest of Europe Minichromosomal Technology, by Application USD Million (2021-2026)
  • Table 181. Rest of Europe Minichromosomal Technology, by End Use USD Million (2021-2026)
  • Table 182. MEA Minichromosomal Technology, by Country USD Million (2021-2026)
  • Table 183. MEA Minichromosomal Technology, by Type USD Million (2021-2026)
  • Table 184. MEA Minichromosomal Technology, by Application USD Million (2021-2026)
  • Table 185. MEA Minichromosomal Technology, by End Use USD Million (2021-2026)
  • Table 186. Middle East Minichromosomal Technology, by Type USD Million (2021-2026)
  • Table 187. Middle East Minichromosomal Technology, by Application USD Million (2021-2026)
  • Table 188. Middle East Minichromosomal Technology, by End Use USD Million (2021-2026)
  • Table 189. Africa Minichromosomal Technology, by Type USD Million (2021-2026)
  • Table 190. Africa Minichromosomal Technology, by Application USD Million (2021-2026)
  • Table 191. Africa Minichromosomal Technology, by End Use USD Million (2021-2026)
  • Table 192. North America Minichromosomal Technology, by Country USD Million (2021-2026)
  • Table 193. North America Minichromosomal Technology, by Type USD Million (2021-2026)
  • Table 194. North America Minichromosomal Technology, by Application USD Million (2021-2026)
  • Table 195. North America Minichromosomal Technology, by End Use USD Million (2021-2026)
  • Table 196. United States Minichromosomal Technology, by Type USD Million (2021-2026)
  • Table 197. United States Minichromosomal Technology, by Application USD Million (2021-2026)
  • Table 198. United States Minichromosomal Technology, by End Use USD Million (2021-2026)
  • Table 199. Canada Minichromosomal Technology, by Type USD Million (2021-2026)
  • Table 200. Canada Minichromosomal Technology, by Application USD Million (2021-2026)
  • Table 201. Canada Minichromosomal Technology, by End Use USD Million (2021-2026)
  • Table 202. Mexico Minichromosomal Technology, by Type USD Million (2021-2026)
  • Table 203. Mexico Minichromosomal Technology, by Application USD Million (2021-2026)
  • Table 204. Mexico Minichromosomal Technology, by End Use USD Million (2021-2026)
  • Table 205. Research Programs/Design for This Report
  • Table 206. Key Data Information from Secondary Sources
  • Table 207. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Minichromosomal Technology: by Type USD Million (2015-2020)
  • Figure 5. Global Minichromosomal Technology: by Application USD Million (2015-2020)
  • Figure 6. Global Minichromosomal Technology: by End Use USD Million (2015-2020)
  • Figure 7. South America Minichromosomal Technology Share (%), by Country
  • Figure 8. Asia Pacific Minichromosomal Technology Share (%), by Country
  • Figure 9. Europe Minichromosomal Technology Share (%), by Country
  • Figure 10. MEA Minichromosomal Technology Share (%), by Country
  • Figure 11. North America Minichromosomal Technology Share (%), by Country
  • Figure 12. Global Minichromosomal Technology share by Players 2020 (%)
  • Figure 13. Global Minichromosomal Technology share by Players (Top 3) 2020(%)
  • Figure 14. Global Minichromosomal Technology share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 17. Thermo Fisher Scientific (United States) Revenue: by Geography 2020
  • Figure 18. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 19. Merck KGaA (Germany) Revenue: by Geography 2020
  • Figure 20. Horizon Discovery Limited (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 21. Horizon Discovery Limited (United Kingdom) Revenue: by Geography 2020
  • Figure 22. Lonza (Switzerland) Revenue, Net Income and Gross profit
  • Figure 23. Lonza (Switzerland) Revenue: by Geography 2020
  • Figure 24. GenScript (United States) Revenue, Net Income and Gross profit
  • Figure 25. GenScript (United States) Revenue: by Geography 2020
  • Figure 26. Eurofins Scientific (Luxembourg) Revenue, Net Income and Gross profit
  • Figure 27. Eurofins Scientific (Luxembourg) Revenue: by Geography 2020
  • Figure 28. Sangamo Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 29. Sangamo Therapeutics (United States) Revenue: by Geography 2020
  • Figure 30. Editas Medicine (United States) Revenue, Net Income and Gross profit
  • Figure 31. Editas Medicine (United States) Revenue: by Geography 2020
  • Figure 32. CRISPR Therapeutics (Switzerland) Revenue, Net Income and Gross profit
  • Figure 33. CRISPR Therapeutics (Switzerland) Revenue: by Geography 2020
  • Figure 34. Precision Biosciences (United States) Revenue, Net Income and Gross profit
  • Figure 35. Precision Biosciences (United States) Revenue: by Geography 2020
  • Figure 36. Global Minichromosomal Technology: by Type USD Million (2021-2026)
  • Figure 37. Global Minichromosomal Technology: by Application USD Million (2021-2026)
  • Figure 38. Global Minichromosomal Technology: by End Use USD Million (2021-2026)
  • Figure 39. South America Minichromosomal Technology Share (%), by Country
  • Figure 40. Asia Pacific Minichromosomal Technology Share (%), by Country
  • Figure 41. Europe Minichromosomal Technology Share (%), by Country
  • Figure 42. MEA Minichromosomal Technology Share (%), by Country
  • Figure 43. North America Minichromosomal Technology Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Thermo Fisher Scientific (United States)
  • Merck KGaA (Germany)
  • Horizon Discovery Limited (United Kingdom)
  • Lonza (Switzerland)
  • GenScript (United States)
  • Eurofins Scientific (Luxembourg)
  • Sangamo Therapeutics (United States)
  • Editas Medicine (United States)
  • CRISPR Therapeutics (Switzerland)
  • Precision Biosciences (United States)
Additional players considered in the study are as follows:
Oxford Genetics (United Kingdom) , Agilent Technologies (United States) , Danaher (United States) , ToolGen (South Korea) , Genecopoeia (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation